MedTrace Logo

Impact of Accu-Chek 360 in Veterans With Type 2 Diabetes

NCT00824694 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 348

Last updated 2011-06-23

No results posted yet for this study

Summary

To show that a structured treatment plan based upon Accu-Chek 360 View has a favorable effect on physician decision-making and HbA1c for patients on oral hypoglycemic agents (OHA) or insulin for type 2 diabetes (T2D).

Hypothesis 1: Compared to controls, intervention subjects will undergo a greater number of medication changes and have a lower HbA1 at the conclusion of the study.

Hypothesis 2: Higher rates of monitoring at entry will be associated with lower CHO consumption, lower percent body fat, higher medication compliance, and higher physical activity levels.

Hypothesis 3: Patients with lower rates of monitoring at entry will have higher rates of depression, more likely to have an external locus of control, and express greater fear about self-testing.

Conditions

Interventions

OTHER

Targeted Self-Monitoring Of Blood Glucose (SMBG)

SMBG will alternate between 2 strategies: glucose profiling and target monitoring.

OTHER

Provider Training

Focused on normalizing the most significant glucose abnormalities at any given time.

OTHER

Patient Education

Focused on normalizing the most significant glucose abnormalities at any given time.

Sponsors & Collaborators

  • New Mexico VA Healthcare System

    collaborator FED

  • Carl T. Hayden VA Medical Center

    collaborator FED

  • Southern Arizona VA Health Care System

    collaborator FED

  • Biomedical Research Institute of New Mexico

    lead OTHER

Principal Investigators

  • Glen H Murata, M.D. · New Mexico VA Healthcare System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00824694 on ClinicalTrials.gov